6,678 trials
Urinary Bladder, Overactive
Primary: Percentage of Participants Who Achieved Treatment Goal — 40.45 Percentage of participants
Eyelash Hypotrichosis · Alopecia Areata
Primary: Percentage of Participants With Adverse Events — 35.4; 43.5 Percentage of participants
Arthritis, Rheumatoid
Primary: Percentage of Participants Achieving American College of Rheumatology Score 20 Percent (ACR20) Response — 63.46; 76.15 Percentage of participants
Diabetes · Diabetes Mellitus, Type 2
Primary: Change in HbA1c (Glycosylated Haemoglobin) - FAS — -0.72; -0.97 percentage of glycosylated haemoglobin
Hernia
Primary: Overall Postsurgical Analgesic Use — 9.7 mg (morphine equivalents)
Heart Failure
Primary: Change in Citrate Synthase Activity as an Estimate of Mitochondrial Activity — -0.3; 0.07 micromole/min/wet weight
Parkinson Disease
Primary: Patient Preference — 17; 31; 13 participants
Prostate Cancer
Primary: Patient Bother From Injection Site Burning and/or Stinging — 23.87; 5.84 units on a scale
Hemophilia A
Primary: Area Under the Plasma Concentration Versus Time Curve From 0 to 48 Hours (AUC 0-48h). Chromogenic Assay — 1158; 1264 (IU·h)/dL — p=0.103
Dementia With Lewy Bodies
Primary: Mean Initial Sleep Latency as Measured by the Maintenance of Wakefulness Test (MWT) — 7.0; 19.0 minutes — p=0.003
Healthy Volunteers
Primary: Duration of Anesthesia(Minutes) — 80; 140; 0; 400 Minutes
Glaucoma · Ocular Hypertension · Open-Angle Glaucoma
Primary: Overall Mean Intraocular Pressure (IOP) — 17.45; 17.22 millimeters mercury (mmHg)
Ossification, Heterotopic
Primary: Percentage of Participants With Heterotopic Ossification (HO) at 6 Months Postoperatively. — 38 percentage of participants
Asthma
Primary: Immunogenicity of Pneumococcal Vaccination — 0.05; 0.05 [µg/ml]
Generalized Anxiety Disorder
Primary: Change From Baseline to Week 10 in Hamilton Anxiety Rating Scale (HAMA) Total Score — -15.86; -11.69 units on a scale — p=<0.001